The prescription retroscope – tools for advocating critical and individualised therapy

Should we give beta-blockers to all patients after myocardial infarction? Beta-blockers have been clearly shown decrease mortality after myocardial infarction, but this was documented more than a quarter of a century ago, before the current revascularisation era, and has become uncertain at the present. Nowadays, the only ironclad indication for cardioprotection with beta-blockers remains heart failure with reduced ejection fraction, the very indication that half a century ago was the only contraindication for beta-blocker therapy.